Stereotaxis Reports Q3 2026 Results with 20% Revenue Growth Amid Supply Chain Constraints
Stereotaxis, Inc. (STXS) reported third-quarter revenue of $8.9 million, a 20% increase year-over-year, driven largely by a 60% surge in system revenue following sales in the U.S. and China. Despite top-line growth, the company faced significant headwinds due to catheter supply shortages caused by manufacturing delays at its German contract manufacturer, Osypka. This shortage resulted in a $1.9 million backlog of disposable orders that could not be converted to revenue. The company's net loss remained consistent with the prior year at $6.5 million. To bolster its financial position and support growth, Stereotaxis secured $24 million in convertible note financing, bringing its pro forma cash balance to $16 million. Management is focusing on scaling catheter production to 500 units per month to meet global demand and mitigate the impact of current supply constraints.
Tickers: $STXS
Topics: acquisition gross margin net loss recurring revenue revenue growth system revenue
Read the full article at Motley Fool
Part of the story Stereotaxis Reports Q3 2026 Results with 20% Revenue Growth Amid Supply Chain Constraints (7 articles)